Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ashvattha Therapeutics Inc.
Headquarters: Redwood City, CA, United States of America
Website: https://avttx.com
Year Founded: 2015
Status: Private
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Jan 10, 2024
Management Tracks
Mark Alles at the helm at Torl
Plus: new CSO at Nutcracker, and updates from
BioCentury | Jun 1, 2023
Management Tracks
Cayer joins Ashvattha as CFO
Plus: Toleikis to continue as Sernova CEO and updates from Hinge and Compass
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Oct 20, 2022
Management Tracks
5AM hires Anna Yaeger as head of public equities
Plus Scripps alum Maricich becomes Ashvattha CMO and updates from Alexion, Rewind, ExeVir and more
BioCentury | Apr 27, 2022
Emerging Company Profile
Ashvattha branches out with $69M series B for dendrimer therapies
JHU spinout advancing COVID-19, ophthalmic programs based on hydroxyl dendrimer platform
Items per page:
1 - 6 of 6